Sponsored Fixing site reads without burning out the readersYunu modernizes clinical trial imaging assessment workflows December 05, 2025Vol.51 No.44By Jeff Sorenson
Free Oncofertility coverage mandates expand to 21 states and DC as political momentum buildsGaps persist as patients face harrowing decisions and huge copays November 21, 2025Vol.51 No.43By Claire Marie Porter and Sara Willa Ernst
Conversation with The Cancer Letter Shane Jacobson talks about his to-do list for ACSBoost research, forge closer ties with cancer centers, launch an all-out campaign for resources November 21, 2025Vol.51 No.43
Guest Editorial My introduction to, and lessons learned from, Rick Pazdur November 21, 2025Vol.51 No.43By Mikkael A. Sekeres
FreeObituary Montefiore Einstein Director Edward Chu dies of glioblastoma at 66 November 21, 2025Vol.51 No.43By Roy S. Herbst, Mario Sznol, Vincent T. DeVita Jr., Robert L. Ferris, Nancy E. Davidson, Otis W. Brawley, Roy A. Jensen, Weijing Sun and Montefiore Einstein staff
FreeObituary Arnold D. Kaluzny, longtime adviser to the NCI and health services researcher, dies at 87 November 21, 2025Vol.51 No.43By Donna M. O’Brien and Barnett Kramer
Sponsored Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration November 21, 2025Vol.51 No.43By The American Society of Clinical Oncology
Conversation with The Cancer LetterRegulatory News Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director November 14, 2025Vol.51 No.42By Paul Goldberg
Guest Editorial Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA November 14, 2025Vol.51 No.42By Ellen V. Sigal
Regulatory News FDA to remove black box warnings on hormone therapy for menopauseTrump-era “gold standard science” is not to be confused with gold standard of scientific evidence November 14, 2025Vol.51 No.42By Claire Marie Porter
